Need help finding what you are looking for?
Contact Us
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2068432
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2068432
Cancer Registry Software Market Insights, Competitive Landscape, and Market Forecast - 2033
PUBLISHED:
PAGES: 196 Pages
DELIVERY TIME: 2-5 business days
SELECT AN OPTION
The cancer registry software market is witnessing strong growth due to the increasing global burden of cancer, rising demand for comprehensive patient data management, and growing emphasis on cancer surveillance programs. Cancer registry software plays a crucial role in collecting, managing, and analyzing cancer-related data, enabling healthcare organizations to improve treatment outcomes, support research initiatives, and enhance public health planning. The market is expected to reach US$245.6 Mn in 2026 and US$614.6 Mn by 2033, growing at a CAGR of 14.00% during the forecast period.
Market Insights:
The industry is undergoing significant transformation driven by advancements in healthcare information technology and the growing adoption of electronic health records. Cancer registry software solutions are increasingly being integrated with hospital information systems to streamline data collection, improve reporting accuracy, and facilitate real-time access to patient information. The growing focus on evidence-based oncology care and population health management is encouraging healthcare providers to adopt advanced registry platforms. Additionally, the integration of artificial intelligence, analytics, and cloud computing technologies is enhancing the efficiency and functionality of cancer registry systems.
Drivers:
Key drivers of the cancer registry software market include the rising incidence of cancer worldwide, increasing government initiatives for cancer surveillance, and growing demand for data-driven healthcare decision-making. Healthcare organizations are focusing on improving patient outcomes through accurate tracking of cancer cases, treatment effectiveness, and survival rates. Regulatory requirements related to cancer reporting and quality improvement programs are further driving software adoption. Moreover, the growing need for centralized databases to support clinical research, epidemiological studies, and healthcare planning is contributing significantly to market growth.
Business Opportunity:
The market presents substantial opportunities for software developers and healthcare technology providers offering cloud-based registry solutions, advanced analytics platforms, and interoperable healthcare data systems. Emerging economies are creating attractive growth prospects due to expanding healthcare infrastructure and increasing investments in digital health initiatives. The adoption of artificial intelligence for predictive analytics, automated data abstraction, and clinical decision support is expected to generate new revenue streams for market participants. Strategic partnerships between healthcare institutions, research organizations, and software vendors are likely to accelerate innovation and market expansion.
Region Analysis:
North America dominates the cancer registry software market owing to its advanced healthcare infrastructure, strong regulatory framework, and widespread adoption of healthcare IT solutions. The region benefits from established cancer surveillance programs and significant investments in oncology research. Europe holds a substantial market share supported by increasing government initiatives for cancer control and growing implementation of digital healthcare systems. Asia Pacific is expected to witness the fastest growth during the forecast period due to rising cancer prevalence, expanding healthcare facilities, and increasing investments in healthcare digitization across countries such as China, India, and Japan. Latin America and the Middle East & Africa are gradually adopting cancer registry technologies as healthcare systems modernize and awareness regarding cancer data management increases.
Key Players:
- Elekta
- Oracle
- ONCO, Inc.
- IBM
- McKesson Corporation
- Conduent, Inc.
- Ordinate Corporation
- Volpara Health Limited
- Health Catalyst
- Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
Segmentation:
By Software Outlook
- Standalone
- Integrated
By Deployment Model Outlook
- On-premise
- Cloud Based
By Component Outlook
- Commercial
- Public
By End-use Outlook
- Government & Third Party
- Private Payers
- Hospital & Medical Practice
- Pharma Biotech & Medical Device Companies
- Research Institutes
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Cancer Registry Software Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2026
- 1.5. Analyst Recommendations
2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. COVID-19 Impact Analysis
- 2.5. Porter's Five Forces Analysis
- 2.6. Impact of Russia-Ukraine Conflict
- 2.7. PESTLE Analysis
- 2.8. Regulatory Analysis
- 2.9. Price Trend Analysis
- 2.9.1. Current Prices and Future Projections, 2025-2033
- 2.9.2. Price Impact Factors
3. Global Cancer Registry Software Market Outlook, 2020-2033
- 3.1. Global Cancer Registry Software Market Outlook, by Software Outlook, Value (US$ Mn), 2020-2033
- 3.1.1. Standalone
- 3.1.2. Integrated
- 3.2. Global Cancer Registry Software Market Outlook, by Deployment Model Outlook, Value (US$ Mn), 2020-2033
- 3.2.1. On-premise
- 3.2.2. Cloud Based
- 3.3. Global Cancer Registry Software Market Outlook, by Component Outlook, Value (US$ Mn), 2020-2033
- 3.3.1. Commercial
- 3.3.2. Public
- 3.4. Global Cancer Registry Software Market Outlook, by End-use Outlook, Value (US$ Mn), 2020-2033
- 3.4.1. Government & Third Party
- 3.4.2. Private Payers
- 3.4.3. Hospital & Medical Practice
- 3.4.4. Pharma Biotech & Medical Device Companies
- 3.4.5. Research Institutes
- 3.5. Global Cancer Registry Software Market Outlook, by Region, Value (US$ Mn), 2020-2033
- 3.5.1. North America
- 3.5.2. Europe
- 3.5.3. Asia Pacific
- 3.5.4. Latin America
- 3.5.5. Middle East & Africa
4. North America Cancer Registry Software Market Outlook, 2020-2033
- 4.1. North America Cancer Registry Software Market Outlook, by Software Outlook, Value (US$ Mn), 2020-2033
- 4.1.1. Standalone
- 4.1.2. Integrated
- 4.2. North America Cancer Registry Software Market Outlook, by Deployment Model Outlook, Value (US$ Mn), 2020-2033
- 4.2.1. On-premise
- 4.2.2. Cloud Based
- 4.3. North America Cancer Registry Software Market Outlook, by Component Outlook, Value (US$ Mn), 2020-2033
- 4.3.1. Commercial
- 4.3.2. Public
- 4.4. North America Cancer Registry Software Market Outlook, by End-use Outlook, Value (US$ Mn), 2020-2033
- 4.4.1. Government & Third Party
- 4.4.2. Private Payers
- 4.4.3. Hospital & Medical Practice
- 4.4.4. Pharma Biotech & Medical Device Companies
- 4.4.5. Research Institutes
- 4.5. North America Cancer Registry Software Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 4.5.1. U.S. Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 4.5.2. U.S. Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 4.5.3. U.S. Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 4.5.4. U.S. Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 4.5.5. Canada Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 4.5.6. Canada Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 4.5.7. Canada Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 4.5.8. Canada Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Cancer Registry Software Market Outlook, 2020-2033
- 5.1. Europe Cancer Registry Software Market Outlook, by Software Outlook, Value (US$ Mn), 2020-2033
- 5.1.1. Standalone
- 5.1.2. Integrated
- 5.2. Europe Cancer Registry Software Market Outlook, by Deployment Model Outlook, Value (US$ Mn), 2020-2033
- 5.2.1. On-premise
- 5.2.2. Cloud Based
- 5.3. Europe Cancer Registry Software Market Outlook, by Component Outlook, Value (US$ Mn), 2020-2033
- 5.3.1. Commercial
- 5.3.2. Public
- 5.4. Europe Cancer Registry Software Market Outlook, by End-use Outlook, Value (US$ Mn), 2020-2033
- 5.4.1. Government & Third Party
- 5.4.2. Private Payers
- 5.4.3. Hospital & Medical Practice
- 5.4.4. Pharma Biotech & Medical Device Companies
- 5.4.5. Research Institutes
- 5.5. Europe Cancer Registry Software Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 5.5.1. Germany Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 5.5.2. Germany Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 5.5.3. Germany Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 5.5.4. Germany Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 5.5.5. Italy Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 5.5.6. Italy Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 5.5.7. Italy Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 5.5.8. Italy Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 5.5.9. France Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 5.5.10. France Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 5.5.11. France Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 5.5.12. France Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 5.5.13. U.K. Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 5.5.14. U.K. Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 5.5.15. U.K. Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 5.5.16. U.K. Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 5.5.17. Spain Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 5.5.18. Spain Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 5.5.19. Spain Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 5.5.20. Spain Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 5.5.21. Russia Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 5.5.22. Russia Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 5.5.23. Russia Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 5.5.24. Russia Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 5.5.25. Rest of Europe Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 5.5.26. Rest of Europe Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 5.5.27. Rest of Europe Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 5.5.28. Rest of Europe Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Cancer Registry Software Market Outlook, 2020-2033
- 6.1. Asia Pacific Cancer Registry Software Market Outlook, by Software Outlook, Value (US$ Mn), 2020-2033
- 6.1.1. Standalone
- 6.1.2. Integrated
- 6.2. Asia Pacific Cancer Registry Software Market Outlook, by Deployment Model Outlook, Value (US$ Mn), 2020-2033
- 6.2.1. On-premise
- 6.2.2. Cloud Based
- 6.3. Asia Pacific Cancer Registry Software Market Outlook, by Component Outlook, Value (US$ Mn), 2020-2033
- 6.3.1. Commercial
- 6.3.2. Public
- 6.4. Asia Pacific Cancer Registry Software Market Outlook, by End-use Outlook, Value (US$ Mn), 2020-2033
- 6.4.1. Government & Third Party
- 6.4.2. Private Payers
- 6.4.3. Hospital & Medical Practice
- 6.4.4. Pharma Biotech & Medical Device Companies
- 6.4.5. Research Institutes
- 6.5. Asia Pacific Cancer Registry Software Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 6.5.1. China Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 6.5.2. China Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 6.5.3. China Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 6.5.4. China Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 6.5.5. Japan Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 6.5.6. Japan Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 6.5.7. Japan Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 6.5.8. Japan Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 6.5.9. South Korea Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 6.5.10. South Korea Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 6.5.11. South Korea Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 6.5.12. South Korea Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 6.5.13. India Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 6.5.14. India Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 6.5.15. India Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 6.5.16. India Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 6.5.17. Southeast Asia Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 6.5.18. Southeast Asia Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 6.5.19. Southeast Asia Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 6.5.20. Southeast Asia Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 6.5.21. Rest of SAO Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 6.5.22. Rest of SAO Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 6.5.23. Rest of SAO Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 6.5.24. Rest of SAO Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Cancer Registry Software Market Outlook, 2020-2033
- 7.1. Latin America Cancer Registry Software Market Outlook, by Software Outlook, Value (US$ Mn), 2020-2033
- 7.1.1. Standalone
- 7.1.2. Integrated
- 7.2. Latin America Cancer Registry Software Market Outlook, by Deployment Model Outlook, Value (US$ Mn), 2020-2033
- 7.2.1. On-premise
- 7.2.2. Cloud Based
- 7.3. Latin America Cancer Registry Software Market Outlook, by Component Outlook, Value (US$ Mn), 2020-2033
- 7.3.1. Commercial
- 7.3.2. Public
- 7.4. Latin America Cancer Registry Software Market Outlook, by End-use Outlook, Value (US$ Mn), 2020-2033
- 7.4.1. Government & Third Party
- 7.4.2. Private Payers
- 7.4.3. Hospital & Medical Practice
- 7.4.4. Pharma Biotech & Medical Device Companies
- 7.4.5. Research Institutes
- 7.5. Latin America Cancer Registry Software Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 7.5.1. Brazil Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 7.5.2. Brazil Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 7.5.3. Brazil Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 7.5.4. Brazil Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 7.5.5. Mexico Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 7.5.6. Mexico Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 7.5.7. Mexico Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 7.5.8. Mexico Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 7.5.9. Argentina Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 7.5.10. Argentina Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 7.5.11. Argentina Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 7.5.12. Argentina Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 7.5.13. Rest of LATAM Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 7.5.14. Rest of LATAM Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 7.5.15. Rest of LATAM Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 7.5.16. Rest of LATAM Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Cancer Registry Software Market Outlook, 2020-2033
- 8.1. Middle East & Africa Cancer Registry Software Market Outlook, by Software Outlook, Value (US$ Mn), 2020-2033
- 8.1.1. Standalone
- 8.1.2. Integrated
- 8.2. Middle East & Africa Cancer Registry Software Market Outlook, by Deployment Model Outlook, Value (US$ Mn), 2020-2033
- 8.2.1. On-premise
- 8.2.2. Cloud Based
- 8.3. Middle East & Africa Cancer Registry Software Market Outlook, by Component Outlook, Value (US$ Mn), 2020-2033
- 8.3.1. Commercial
- 8.3.2. Public
- 8.4. Middle East & Africa Cancer Registry Software Market Outlook, by End-use Outlook, Value (US$ Mn), 2020-2033
- 8.4.1. Government & Third Party
- 8.4.2. Private Payers
- 8.4.3. Hospital & Medical Practice
- 8.4.4. Pharma Biotech & Medical Device Companies
- 8.4.5. Research Institutes
- 8.5. Middle East & Africa Cancer Registry Software Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 8.5.1. GCC Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 8.5.2. GCC Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 8.5.3. GCC Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 8.5.4. GCC Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 8.5.5. South Africa Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 8.5.6. South Africa Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 8.5.7. South Africa Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 8.5.8. South Africa Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 8.5.9. Egypt Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 8.5.10. Egypt Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 8.5.11. Egypt Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 8.5.12. Egypt Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 8.5.13. Nigeria Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 8.5.14. Nigeria Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 8.5.15. Nigeria Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 8.5.16. Nigeria Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 8.5.17. Rest of Middle East Cancer Registry Software Market Outlook, by Software Outlook, 2020-2033
- 8.5.18. Rest of Middle East Cancer Registry Software Market Outlook, by Deployment Model Outlook, 2020-2033
- 8.5.19. Rest of Middle East Cancer Registry Software Market Outlook, by Component Outlook, 2020-2033
- 8.5.20. Rest of Middle East Cancer Registry Software Market Outlook, by End-use Outlook, 2020-2033
- 8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
- 9.1. Company Vs Segment Heatmap
- 9.2. Company Market Share Analysis, 2025
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Elekta
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Developments
- 9.4.2. Oracle
- 9.4.3. ONCO, Inc.
- 9.4.4. IBM
- 9.4.5. MCKESSON CORPORATION
- 9.4.6. Conduent, Inc.
- 9.4.7. Ordinate Corporation
- 9.4.8. Volpara Health Limited
- 9.4.9. Health Catalyst
- 9.4.10. Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
- 9.4.1. Elekta
10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.